Journal of Pathology and Translational Medicine10.4132/jptm.2021.07.152021555324-329Robust home brew fragment sizing assay for detection of MET exon 14 skipping mutation in non–small cell lung cancer patients in resource constrained community hospitalsAnurag Mehta, Shrinidhi Nathany, Aanchal Chopra, Sakshi Mattoo, Dushyant Kumar, Manoj Kumar Panigrahi,,
Clinical Lung Cancer10.1016/j.cllc.2018.12.0022019203e418-e420MET Immunohistochemistry Should Be Avoided in Selecting Non–small-cell Lung Cancers Requiring MET Exon 14 Skipping Mutation AnalysisLaetitia Lambros, Arnaud Uguen,
Lung Cancer10.1016/j.lungcan.2021.02.0302021154142-145MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapySelina K. Wong, Deepu Alex, Ian Bosdet, Curtis Hughesman, Aly Karsan, Stephen Yip, Cheryl Ho,
Expert Review of Anticancer Therapy10.1080/14737140.2021.19246832021218877-886Detection of MET exon 14 skipping mutations in non-small cell lung cancer: overview and community perspectiveJanakiraman Subramanian, Ossama Tawfik
Thoracic Cancer10.1111/1759-7714.137902020124549-552Interstitial lung disease associated with capmatinib therapy in a patient with non‐small cell lung cancer harboring a skipping mutation of MET exon 14Hiroaki Kanemura, Masayuki Takeda, Shigeki Shimizu, Kazuhiko Nakagawa,,
Cancer Genetics10.1016/j.cancergen.2021.04.0052021256-25762-67Novel MET exon 14 skipping analogs characterized in non-small cell lung cancer patients: A case studyMinke Shi, Jing Ma, Meilin Feng, Lei Liang, Hongyuan Chen, Tao Wang, Zhenghua Xie,
Cancer Treatment Reviews10.1016/j.ctrv.2021.102173202195102173Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studiesYi-Long Wu, Egbert F. Smit, Todd M. Bauer,
Journal of Thoracic Oncology10.1016/j.jtho.2021.01.12272021163S670-S671P85.05 MET Exon 14 Skipping Mutation Positive Non-Small Cell Lung Cancer: A Population-Based CohortS. Wong, D. Alex, I. Bosdet, C. Hughesman, A. Karsan, S. Yip, C. Ho,
Cancer Treatment Reviews10.1016/j.ctrv.2020.102022202087102022The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skippingRavi Salgia, Martin Sattler, Juergen Scheele, Christopher Stroh, Enriqueta Felip,
Lung Cancer10.1016/j.lungcan.2016.11.011201710327-37The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the InevitableThanyanan Reungwetwattana, Ying Liang, Viola Zhu, Sai-Hong Ignatius Ou,